SPP1 expression indicates outcome of immunotherapy plus tyrosine kinase inhibition in advanced renal cell carcinoma

References

• Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, Heng DY, Larkin J, Ficarra V. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3(1):17009. doi:10.1038/nrdp.2017.9.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Motzer RJ, Longo DL. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354–13. doi:10.1056/NEJMra1601333.
   PubMed Web of Science ®Google Scholar
• Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13(3):688–96. doi:10.1200/JCO.1995.13.3.688.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, Bedke J, Capitanio U, Dabestani S, Fernández-Pello S, Giles RH, Hofmann F, Hora M, et al. European association of urology guidelines on renal cell carcinoma: the 2022 update. Eur Urol. 2022;82(4):399–410. doi:10.1016/j.eururo.2022.03.006.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S, Uemura M, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103–15. doi:10.1056/NEJMoa1816047.
   PubMed Web of Science ®Google Scholar
• Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116–27. doi:10.1056/NEJMoa1816714.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378(14):1277–90. doi:10.1056/NEJMoa1712126.
   PubMed Web of Science ®Google Scholar
• Hao C, Lane J, Jiang WG. Osteopontin and cancer: insights into its role in drug resistance. Biomedicines. 2023;11(1):197. doi:10.3390/biomedicines11010197.
   PubMed Web of Science ®Google Scholar
• Yan CH, Lv M, Li H, Song X, Yan F, Cao S, Ren X. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection. J Cancer Res Clin Oncol. 2015;141(8):1371–8. doi:10.1007/s00432-014-1902-1.
   PubMed Web of Science ®Google Scholar
• Zhao H, Chen Q, Alam A, Cui J, Suen KC, Soo AP, Eguchi S, Gu J, Ma D. The role of osteopontin in the progression of solid organ tumour. Cell Death Disease. 2018;9(3):356. doi:10.1038/s41419-018-0391-6.
   PubMedGoogle Scholar
• Wei R, Wong JPC, Kwok HF. Osteopontin – a promising biomarker for cancer therapy. J Cancer. 2017;8(12):2173–83. doi:10.7150/jca.20480.
   PubMed Web of Science ®Google Scholar
• Huang X, Qian Y, Wu H, Xie X, Zhou Q, Wang Y, Kuang W, Shen L, Li K, Su J, et al. Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma. J Histochem Cytochem. 2015;63(2):88–98. doi:10.1369/0022155414561329.
   PubMed Web of Science ®Google Scholar
• Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, Chen C-H, Chiu T-J. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int. 2015;2015:1–13. doi:10.1155/2015/508587.
   Web of Science ®Google Scholar
• Ding K, Fan Lu, Chen S, Wang Y, Yu H, Sun Y, Yu J, Wang Li, Liu X, Liu Y, et al. Overexpression of osteopontin promotes resistance to cisplatin treatment in HCC. Oncol Rep. 2015;34(6):3297–303. doi:10.3892/or.2015.4306.
   PubMed Web of Science ®Google Scholar
• Cui J, Wang J, Lin C, Liu J, Zuo W. Osteopontin mediates cetuximab resistance via the MAPK pathway in NSCLC cells. Onco Targets Ther. 2019;12:10177–85. doi:10.2147/OTT.S228437.
   PubMed Web of Science ®Google Scholar
• Chakraborty S, Li L, Puliyappadamba VT, Guo G, Hatanpaa KJ, Mickey B, Souza RF, Vo P, Herz J, Chen M-R, et al. Constitutive and ligand-induced EGFR signalling triggers distinct and mutually exclusive downstream signalling networks. Nat Commun. 2014;5(1):5811. doi:10.1038/ncomms6811.
   PubMedGoogle Scholar
• Moorman HR, Poschel D, Klement JD, Lu C, Redd PS, Liu K. Osteopontin: a key regulator of tumor progression and immunomodulation. Cancers Basel. 2020;12(11):3379. doi:10.3390/cancers12113379.
   PubMed Web of Science ®Google Scholar
• Klement JD, Paschall AV, Redd PS, Ibrahim ML, Lu C, Yang D, Celis E, Abrams SI, Ozato K, Liu K. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 2018;128(12):5549–60. doi:10.1172/JCI123360.
   PubMed Web of Science ®Google Scholar
• Wei J, Marisetty A, Schrand B, Gabrusiewicz K, Hashimoto Y, Ott M, Grami Z, Kong L-Y, Ling X, Caruso H, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129(1):137–49. doi:10.1172/JCI121266.
   PubMed Web of Science ®Google Scholar
• Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy. Cancer Immunol Immunother. 2009;58(1):49–59. doi:10.1007/s00262-008-0523-4.
   PubMed Web of Science ®Google Scholar
• Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182(8):4499–506. doi:10.4049/jimmunol.0802740.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang S, Wang Y, Zhu Y, Xu X, Guo J. Alternative complement pathway signature determines immunosuppression and resistance to immunotherapy plus tyrosine kinase inhibitor combinations in renal cell carcinoma. Urol Oncol. 2023;41(1):51.13–23. doi:10.1016/j.urolonc.2022.09.009.
   Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the xena platform. Nat Biotechnol. 2020;38(6):675–8. doi:10.1038/s41587-020-0546-8.
   PubMed Web of Science ®Google Scholar
• Wang J, Liu L, Bai Q, Ou C, Xiong Y, Qu Y, Wang Z, Xia Y, Guo J, Xu J, et al. Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma. Oncoimmunology. 2019;8(1):e1515611. doi:10.1080/2162402X.2018.1515611.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Chen Z, Zhu Y, Wang J, Guo J. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Immunogenetics. 2022;75(2):133–43. doi:10.1007/s00251-022-01292-3.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–41. doi:10.1056/NEJMoa2026982.
   PubMed Web of Science ®Google Scholar
• Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ, et al. Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med. 2021;384(14):1289–300. doi:10.1056/NEJMoa2035716.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Robbins PB, Powles T, Albiges L, Haanen JB, Larkin J, Mu XJ, Ching KA, Uemura M, Pal SK, et al. Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial. Nat Med. 2020;26(11):1733–41. doi:10.1038/s41591-020-1044-8.
   PubMed Web of Science ®Google Scholar
• McDermott DF, Huseni MA, Atkins MB, Motzer RJ, Rini BI, Escudier B, Fong L, Joseph RW, Pal SK, Reeves JA, et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat Med. 2018;24(6):749–57. doi:10.1038/s41591-018-0053-3.
   PubMed Web of Science ®Google Scholar
• Braun DA, Hou Y, Bakouny Z, Ficial M, Sant’ Angelo M, Forman J, Ross-Macdonald P, Berger AC, Jegede OA, Elagina L, et al. Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma. Nat Med. 2020;26(6):909–18. doi:10.1038/s41591-020-0839-y.
   PubMed Web of Science ®Google Scholar
• Xu X, Zhang S, Wang Y, Zhu Y, Wang J, Guo J. HMOX1 pathway signature predicts clinical benefit from immunotherapy plus tyrosine kinase inhibitor therapy in advanced renal cell carcinoma. Cancer Med. 2023;12(9):10512–25. doi:10.1002/cam4.5787.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang S, Wang Y, Zhu Y, Xu X, Guo J. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma. BMC Urol. 2024;24(1):8. doi:10.1186/s12894-023-01356-w.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Chen Z, Zhu Y, Wang J, Guo J. Favorable immunotherapy plus tyrosine kinase inhibition outcome of renal cell carcinoma patients with low CDK5 expression. Cancer Res Treat. 2023;55(4):1321–36. doi:10.4143/crt.2022.1532.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Hu X, Zhu Y, Wang J, Guo J. Effects of PYCR1 on prognosis and immunotherapy plus tyrosine kinase inhibition responsiveness in metastatic renal cell carcinoma patients. Neoplasia. 2023;43:100919. doi:10.1016/j.neo.2023.100919.
   PubMed Web of Science ®Google Scholar
• Xu X, Wang Y, Chen Z, Zhu Y, Wang J, Guo J. Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression. Immunogenetics. 2023;75(2):133–43. doi:10.1007/s00251-022-01292-3.
   PubMed Web of Science ®Google Scholar
• Rabjerg M. Identification and validation of novel prognostic markers in renal cell carcinoma. Dan Med J. 2017;64(10).
   PubMed Web of Science ®Google Scholar
• Nishikawa H, Kato T, Tawara I, Saito K, Ikeda H, Kuribayashi K, Allen PM, Schreiber RD, Sakaguchi S, Old LJ, et al. Definition of target antigens for naturally occurring CD4(+) CD25(+) regulatory T cells. J Exp Med. 2005;201(5):681–6. doi:10.1084/jem.20041959.
   PubMed Web of Science ®Google Scholar
• Chaudary N, Hill RP. Hypoxia and metastasis. Clin Cancer Res. 2007;13(7):1947–9. doi:10.1158/1078-0432.CCR-06-2971.
   PubMed Web of Science ®Google Scholar
• Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol Immunother. 2011;60(7):909–18. doi:10.1007/s00262-011-1046-y.
   PubMed Web of Science ®Google Scholar
• Bron L, Jandus C, Andrejevic‐Blant S, Speiser DE, Monnier P, Romero P, Rivals J-P. Prognostic value of arginase-II expression and regulatory T-cell infiltration in head and neck squamous cell carcinoma. Int J Cancer. 2013;132(3):E85–93. doi:10.1002/ijc.27728.
   PubMed Web of Science ®Google Scholar
• Li Y, Ding L, Zhang Y, Zhou B, Wai Man GC, Wang M, Li J, Liu Y, Lin W, Wang H, et al. Histone demethylase Kdm5c regulates osteogenesis and bone formation via PI3K/Akt/HIF1α and Wnt/β-catenin signaling pathways. Genes Dis. 2024;11(1):64–6. doi:10.1016/j.gendis.2023.02.041.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Wang C-Y, Gao C, Chen J-D, Chen J-J, Wang Z, Ju L-G, Tang S-B, Yao J, Li F, et al. Regulation of KDM5C stability and enhancer reprogramming in breast cancer. Cell Death Disease. 2022;13(10):843. doi:10.1038/s41419-022-05296-5.
   PubMed Web of Science ®Google Scholar
• Chen XJ, Ren AQ, Zheng L, Zheng ED. Predictive value of KDM5C alterations for immune checkpoint inhibitors treatment outcomes in patients with cancer. Front Immunol. 2021;12:664847. doi:10.3389/fimmu.2021.664847.
   PubMedGoogle Scholar
• Zheng Q, Li P, Zhou X, Qiang Y, Fan J, Lin Y, Chen Y, Guo J, Wang F, Xue H, et al. Deficiency of the X-inactivation escaping gene KDM5C in clear cell renal cell carcinoma promotes tumorigenicity by reprogramming glycogen metabolism and inhibiting ferroptosis. Theranostics. 2021;11(18):8674–91. doi:10.7150/thno.60233.
   PubMed Web of Science ®Google Scholar